We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+10.21%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$847M
AUM Growth
–
Cap. Flow
+$832M
Cap. Flow %
98.22%
Top 10 Hldgs %
74.89%
Holding
32
New
32
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$122M
2
VPHM
VIROPHARMA INC
VPHM
+$105M
3
CYBX
CYBERONICS INC
CYBX
+$88.3M
4
UTHR icon
United Therapeutics
UTHR
+$58M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$49.1M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 34.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONXX
1
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
$115M 13.58%
+1,325,115
New +$122M
VPHM
2
DELISTED
VIROPHARMA INC
VPHM
$114M 13.42%
+3,968,818
New +$105M
CYBX
3
DELISTED
CYBERONICS INC
CYBX
$96.8M 11.43%
+1,863,118
New +$88.3M
UTHR icon
4
United Therapeutics
UTHR
$23.1B
$59.3M 7%
+900,778
New +$58M
ABMD
5
DELISTED
Abiomed Inc
ABMD
$50M 5.9%
+2,319,398
New +$46.6M
AUXL
6
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$47.4M 5.59%
+2,847,842
New +$45.5M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12.4B
$43.9M 5.18%
+787,119
New +$49.1M
AMAG
8
DELISTED
AMAG Pharmaceuticals
AMAG
$37.4M 4.41%
+1,680,871
New +$37M
CBST
9
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$36.5M 4.31%
+756,821
New +$37.2M
SQNM
10
DELISTED
SEQUENOM INC NEW
SQNM
$34.5M 4.08%
+8,202,692
New +$32.8M
STAA icon
11
STAAR Surgical
STAA
$1.21B
$32.6M 3.85%
+3,211,318
New +$26M
QCOR
12
DELISTED
QUESTCOR PHARMA INC
QCOR
$31.6M 3.73%
+696,297
New +$24.7M
VNDA icon
13
Vanda Pharmaceuticals
VNDA
$302M
$19.2M 2.27%
+2,381,876
New +$16M
ALIM
14
DELISTED
Alimera Sciences
ALIM
$17.7M 2.09%
+242,332
New +$14M
MNTA
15
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$17.7M 2.09%
+1,175,076
New +$15.5M
ITMN
16
DELISTED
INTERMUNE INC
ITMN
$17.1M 2.02%
+1,775,485
New +$16.9M
RIGL icon
17
Rigel Pharmaceuticals
RIGL
$750M
$13.1M 1.55%
+393,558
New +$17.8M
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
$10.8M 1.27%
+4,622,230
New +$14.2M
ANAC
19
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$9.04M 1.07%
+1,617,651
New +$9.79M
AVEO
20
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$8.77M 1.04%
+350,921
New +$15M
QLTI
21
DELISTED
QLT Inc
QLTI
$8.56M 1.01%
+1,950,636
New +$15.7M
SVNT
22
DELISTED
SAVIENT PHARMACEUTICALS INC
SVNT
$5.46M 0.64%
+9,744,833
New +$6.79M
INSM icon
23
Insmed
INSM
$28.6B
$3.19M 0.38%
+266,299
New +$2.72M
AEGR
24
DELISTED
Aegerion Pharmaceuticals
AEGR
$3.11M 0.37%
+49,040
New +$2.6M
CYTK icon
25
Cytokinetics
CYTK
$10.4B
$3.03M 0.36%
+261,544
New +$2.06M
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Palo Alto Investors, which disclosed 32 positions worth $847M. Its ten largest holdings account for 75% of the portfolio.

Its largest position is ONYX PHARMACEUTICALS INC: 1,325,115 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets.

  • Palo Alto Investors's largest Q2 2013 buy was ONYX PHARMACEUTICALS INC: 1,325,115 shares worth $115M.
  • Palo Alto Investors's ten largest holdings make up 75% of its $847M portfolio in Q2 2013.
  • Palo Alto Investors disclosed 32 positions in Q2 2013, its first 13F filing on record.

Based on Palo Alto Investors's 13F filing for Q2 2013, filed 14 Aug 2013.